GANX
Overvalued by 72.9% based on the discounted cash flow analysis.
Market cap | $58.99 Million |
---|---|
Enterprise Value | $52.47 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-0.89 |
Beta | 0.11 |
Outstanding Shares | 28,685,417 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -2.7 |
---|---|
PEG | -21.01 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -2.58 |
Enterprise Value to Net Income | -3 |
Total Debt to Enterprise | 0.05 |
Debt to Equity | 0.44 |
No data
No data
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...